Schrodinger, Inc. splits its revenue 2 ways in its filings. By operating segments, the largest line in fiscal 2025, which ended Dec 31, 2025 was Software at $199.5 million, 78% of the total. By sales mix, the largest line in fiscal 2025, which ended Dec 31, 2025 was Software Products And Services at $199.5 million, 78% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
|---|---|---|---|---|---|---|---|
| Revenue |
269
|
256
|
208
|
217
|
181
|
138
|
108
|
| Operating segments | |||||||
| Software |
181
-14.0%
share 67.1%
|
200
+10.6%
share 78.0%
|
180
+13.3%
share 86.9%
|
159
+17.4%
share 73.4%
|
136
share 74.9%
|
—
|
—
|
| Drug Discovery |
89
+88.3%
share 32.9%
|
56
+107.4%
share 22.0%
|
27
-52.8%
share 13.1%
|
58
+26.8%
share 26.6%
|
45
share 25.1%
|
—
|
—
|
| Sales mix | |||||||
| Software Products And Services |
189
-4.0%
share 70.1%
|
200
+10.6%
share 78.0%
|
180
share 86.9%
|
—
|
—
|
—
|
—
|
| Hosted Software |
56
+25.1%
share 20.8%
|
45
share 17.6%
|
—
|
20
+36.9%
share 9.4%
|
15
+34.4%
share 8.2%
|
11
+20.5%
share 8.0%
|
9
share 8.5%
|
| Professional Services |
13
+54.6%
share 4.7%
|
10
-1.5%
share 3.8%
|
10
+4.6%
share 4.7%
|
9
-38.4%
share 4.3%
|
15
+64.1%
share 8.4%
|
9
-3.1%
share 6.7%
|
10
share 8.8%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SDGR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1490978
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.